BioSpace News Archive

iPredictTM AI Eye Screening System provides fully automated diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma suspect screening, including retinal imaging, and immediate reporting of actionable results.

Rise in geriatric population, across the world, has given way to widespread diseases including neurological syndromes, ophthalmic impairment, and several cardiovascular issues.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference.

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its first quarter 2022 financial results after the market closes on Tuesday, May 3, 2022.

Retractable Technologies, Inc. (NYSE American: RVP) reports that, effective April 14, 2022, it has terminated its Rule 10b5-1/10b-18 Repurchase Plan dated June 4, 2021.

Takeda announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for Nuvaxovid® Intramuscular Injection, a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Phio Pharmaceuticals Corp. today announced that in vivo data showing PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response was selected for an encore presentation at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop, which is being held April 21st – 22nd in San Diego and virtually.

This compares to up to 10 days using conventional antibiotic treatments as the current standard of care. E. coli (Escherichia coli) is the leading cause of urinary tract, ear, wound and other infections in humans[1] and has been shown to develop antibiotic resistance in as little as 11 days.